The FDA has authorized the emergency use of Evusheld for use as pre-exposure prophylaxis of COVID-19 in certain adults and pediatric patients who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and meet either condition below:

  • Those with moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medication or treatments and may not mount an adequate immune response to COVID-19 vaccination, or
  • For whom vaccination with any available COVID-19 vaccine in not recommended due to a history of severe adverse reaction to a COVID-19 vaccines(s) and/or COVID-19 vaccine(S) component(s).

REMEMBER: Evusheld is not authorized for use as a treatment of COVID-19 or as post-exposure prophylaxis of COVID-19. Evusheld cannot be administered for at least two weeks after receiving a COVID-19 vaccination or booster.

As of June 29, 2022, the FDA has updated its recommendations for repeat Evusheld dosing to be every six months for as long as a patient needs ongoing protection. Repeat dosing should be timed from the date of the most recent Evusheld dose.

Download Evusheld Fact Sheet

Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include but are not limited to:

  • Active treatment for solid tumor and hematologic malignancies
  • Receipt of solid-organ transplant and taking immunosuppressive therapy
  • Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
  • Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
  • Advanced or untreated HIV infection (people with HIV and CD4 cell counts

Prioritization Tiers:

  • Received B-cell depleting therapies (e.g. rituximab, Obinutuzumab, ocrelizumab, alemtuzumab) within the last 6 month and is over the age of 66
  • Received B-cell depleting therapies, within the last 6 months, and is under the age of 65. Any ongoing use of BTK inhibitors (ibrutinib, acalabrutinib)
  • Received allogenic HCT or CAR-T therapy within the past 6-12 months
  • Lung transplants, other SOT recipients on continual belatacept therapy, or multiple myeloma (actively receiving treatment)
  • Autologous HCT, or other solid organ transplants over the age of 65 and withing 6 months of transplant
  • Other actively treated hematologic malignancies or severe congenital immunodeficiency syndromes; patients receiving high-dose cyclophosphamide or similarly immunosuppressive regimens
  • Solid tumor malignancies or inflammatory syndromes on immunomodulatory chemotherapy (e.g: high-dose cyclophosphamide); advanced AIDS


  • EVUSHELD is not authorized for use in individuals:
    • For treatment of COVID-19, or
    • For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2.
  • Pre-exposure prophylaxis with EVUSHELD is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended.
    • Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate to severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID-19 vaccination.
  • In individuals who have received a COVID-19 vaccine, EVUSHELD should be administered at least two weeks after vaccination.

Additional Information:

  • St. Charles has a limited supply of Evusheld
  • Prioritization is given to high-risk patients
  • The Cancer Infusion Center (Bend location) is the only site offering Evusheld
  • Injections are available Monday – Friday
  • Evusheld requires 60 min observation time following administration
  • All patients must abide by current Covid Screening and Visitor policies

Ordering Evusheld

  • Providers can order this treatment for their patients through Epic or using the online form button below.
  • To order in Epic search LAAB Injection in the preference list or database.
  • Once the referral is reviewed by the pharmacy team, the patient will be contacted to schedule.

Evusheld Treatment Order Form